SO
AIMT

STRS Ohio’s Aimmune Therapeutics AIMT Stock Holding History

STRS Ohio’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-24,300
Closed -$687K – 2213
2018
Q2 		$653K Buy
24,300
+2,200
+10% +$67.3K ﹤0.01% 1236
2018
Q1 		$703K Buy
22,100
+2,800
+15% +$98.5K ﹤0.01% 1126
2017
Q4 		$729K Hold
19,300
– – ﹤0.01% 1076
2017
Q3 		$478K Sell
19,300
-15,300
-44% -$330K ﹤0.01% 1365
2017
Q2 		$711K Buy
34,600
+2,000
+6% +$38.2K ﹤0.01% 1078
2017
Q1 		$708K Sell
32,600
-1,300
-4% -$26.7K ﹤0.01% 1081
2016
Q4 		$693K Buy
+33,900
New +$693K ﹤0.01% 1130
2016
Q2 		– Sell
-3,600
Closed -$48K – 2046
2016
Q1 		$48K Hold
3,600
– – ﹤0.01% 1769
2015
Q4 		$66K Hold
3,600
– – ﹤0.01% 1751
2015
Q3 		$91K Buy
+3,600
New +$84.2K ﹤0.01% 1675

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

STRS Ohio's AIMT Position: Q3 2018 in Review

STRS Ohio sold out of Aimmune Therapeutics (AIMT) in Q3 2018, closing a stake of 24,300 shares — an estimated $687K sold.

STRS Ohio first reported a position in AIMT in Q3 2015 and held it in 10 quarters. The position peaked at $729K in Q4 2017. 142 funds tracked by Wall St. Rank hold AIMT as of Q3 2018.

  • STRS Ohio reported no remaining Aimmune Therapeutics position as of Q3 2018 after selling out during the quarter.
  • STRS Ohio sold 24,300 Aimmune Therapeutics shares in Q3 2018, an estimated $687K.
  • STRS Ohio first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 10 quarters.
  • STRS Ohio's Aimmune Therapeutics position peaked at $729K in Q4 2017.
  • 142 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2018.

Based on STRS Ohio's 13F filing for Q3 2018, filed 19 Oct 2018.